IPN Ipsen SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2025

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2025

Présentation agrégée par jour et par marché

Déclaration des transactions sur actions propres réalisées du 09 juin au 13 juin 2025
       
Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marché
IPSEN549300M6SGDPB4Z94P1109/06/2025FR0010259150   320   104,26875AQEU
IPSEN549300M6SGDPB4Z94P1109/06/2025FR0010259150  1 050   104,1799CCXE
IPSEN549300M6SGDPB4Z94P1109/06/2025FR0010259150   584   104,16798TQEX
IPSEN549300M6SGDPB4Z94P1109/06/2025FR0010259150  2 646   104,14463XPAR
IPSEN549300M6SGDPB4Z94P1110/06/2025FR0010259150   309   104,54498AQEU
IPSEN549300M6SGDPB4Z94P1110/06/2025FR0010259150   850   104,58471CCXE
IPSEN549300M6SGDPB4Z94P1110/06/2025FR0010259150   275   104,54TQEX
IPSEN549300M6SGDPB4Z94P1110/06/2025FR0010259150  3 166   104,50076XPAR
IPSEN549300M6SGDPB4Z94P1111/06/2025FR0010259150   100   103,50AQEU
IPSEN549300M6SGDPB4Z94P1111/06/2025FR0010259150   300   103,73333CCXE
IPSEN549300M6SGDPB4Z94P1111/06/2025FR0010259150   100   103,50TQEX
IPSEN549300M6SGDPB4Z94P1111/06/2025FR0010259150  3 882   103,46515XPAR
IPSEN549300M6SGDPB4Z94P1112/06/2025FR0010259150   100   103,80AQEU
IPSEN549300M6SGDPB4Z94P1112/06/2025FR0010259150   200   103,75CCXE
IPSEN549300M6SGDPB4Z94P1112/06/2025FR0010259150  3 700   103,53073XPAR
IPSEN549300M6SGDPB4Z94P1113/06/2025FR0010259150   340   103,56471AQEU
IPSEN549300M6SGDPB4Z94P1113/06/2025FR0010259150  1 123   103,37498CCXE
IPSEN549300M6SGDPB4Z94P1113/06/2025FR0010259150   295   103,49492TQEX
IPSEN549300M6SGDPB4Z94P1113/06/2025FR0010259150  4 648   103,29701XPAR
   TOTAL23 988 103,7843 



Pièce jointe



EN
17/06/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

18h / 56m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

18h / 56m 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch